The Anomali Platform Advances Intelligence-Driven Detection and Response Capabilities and Prevents Business Disruptions While Optimizing Security Expense
15.9.2022 02:46:00 EEST | Business Wire | Press release
Anomali, the leader in intelligence-driven cybersecurity solutions, announced the general availability today of its quarterly platform update to meet the expanding needs of its customers and partners. This release introduces new capabilities to enhance Anomali’s threat intelligence and extended detection and response (XDR) use cases that enable enterprise organizations to stay one step ahead of adversaries and prevent business disruptions while optimizing security expenses.
“Anomali’s August release offers new capabilities and enhancements for security operations teams struggling to identify not only who’s targeting them, but how and why they are being targeted,” said Mark Alba, Chief Product Officer at Anomali.
Key highlights of this release include:
Creating Extended Visibility with Anomali Attack Pattern Detection and MITRE ATT&CK®: In 2021, Anomali joined MITRE Engenuity’s Center for Threat-Informed Defense to collaborate on the Attack Flow Project to better understand adversary behavior and improve defensive capabilities. This partnership culminated with the public release of the project in March 2022.
Since then, Anomali has been working to incorporate attack flows into The Anomali Platform. This release moves the platform toward an Attack Flow Library for Anomali ThreatStream that will provide an access point for new Attack Flows that sequence cyberattack techniques. This capability will provide a new context around adversary behavior and help security teams expertly profile the adversary. It will also enable them better to protect the organization in advance of an attack, detect an attack in real-time, and respond post-attack.
Furthermore, this predictive visual mapping will be leveraged by CISOs and security professionals to align attacks with potential holes in their security posture to get in front of the threat.
“ESG research found that 97% of security professionals believe that MITRE ATT&CK is important to their organization’s security operations strategy,” said Jon Oltsik, Senior Principal Analyst and Fellow, ESG Research. “Anomali’s commitment to integrating the MITRE ATT&CK Framework into its solutions and participating in the MITRE Engenuity Center for Threat Informed Defense can help security teams adopt the framework and better understand cyber-adversaries.”
Routine Workflow Automation: Given macro-economic conditions, customers are looking for capabilities that make their existing investments more impactful. We’ve introduced a new extensible framework to support the automation of routine tasks throughout the platform. This release's first implementation is available to automate enrichments in the investigations workbench. A drag-and-drop process for configuring a multi-stage enrichment task can easily be set and run when conditions require it, saving analysts time performing repetitive tasks.
Additional enhancements with this platform release include:
- Support for MITRE ATT&CK Mobile & ICS: Intelligence aggregation, contextualization, and analysis for Mobile and ICS attack surfaces to strengthen overall security posture.
- MITRE ATT&CK Enterprise v11 in Anomali Lens
- Scheduled Retrospective Search: Helps the SOC automate the correlation of historical events with newly available intelligence to produce reports and gain insight into threat actors, TTPs, or other adversary behavior. This new capability enables CISOs to detect real-time threats in their local IT environment.
Anomali will be exhibiting at BlackHat on August 10 & 11, Booth #3034. Stop by to chat with the team and learn more about our intelligence-driven solutions.
About Anomali
Anomali is the leader in intelligence-driven extended detection and response (XDR) cybersecurity solutions. Anchored by big data management (the “X”) and refined by artificial intelligence, The Anomali Platform, an XDR solution, delivers unique proprietary capabilities that correlate the largest repository of global intelligence with telemetry from customer-deployed security solutions. This combination empowers security operations teams to accurately detect threats, optimize response, achieve resiliency, and ultimately stop attackers and breaches. Our SaaS-based solutions easily integrate into existing security tech stacks through native-cloud, multi-cloud, on-premises, and hybrid deployments. Founded in 2013, Anomali serves global B2B enterprise businesses, large public sector organizations, ISACs, ISAOs, service providers, and Global 1000 customers to help safeguard the world’s critical infrastructure, companies, and people. Leading venture firms, including Google Ventures, General Catalyst, and IVP, back Anomali. Learn more at www.anomali.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220808005789/en/
Contact information
Karen Buffo
news@anomali.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 202620.10.2026 16:02:00 EEST | Press release
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 25 abstracts—including five rapid oral presentations—demonstrating advances in methylation-based circulating tumor DNA (ctDNA) monitoring and liquid biopsy technology across lung, colorectal, and gastric cancers at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27 in Madrid, Spain. The studies span Guardant's cancer portfolio, including tissue-free minimal residual disease (MRD) surveillance, treatment response, and resistance research. Significant studies were conducted independently by industry collaborators, academic institutions, and Guardant’s public-private partners using the company’s technologies and/or real-world data, underscoring the wide adoption of its platform across the research community. “At ESMO, we will showcase how InfinityAI is advancing our portfolio, strengthening the clinic
First Cessna Citation CJ4 Gen3 Advances Toward Entry Into Service as First Production Unit Rolls out of the Factory20.10.2026 16:00:00 EEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, recently celebrated the rollout of the first production unit of the Cessna Citation CJ4 Gen3, an important milestone as the aircraft advances toward entry into service. The rollout represents Textron Aviation's continued investment in the light jet lineup, bringing Garmin G3000 PRIME avionics, Garmin Emergency Autoland and other customer-driven enhancements to the proven Citation CJ4 platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261020982419/en/ First Cessna Citation CJ4 Gen3 advances toward entry into service as first production unit rolls out of the factory. (Photo credit: Textron Aviation) “This rollout is a visible result of the care, precision and teamwork that move an aircraft from design intent to a production-ready airplane,” said Eric Cardinali, senior vice president, Manufacturing Operations. “For our manufacturing teams, it represents the discipl
ARIS Launches Process Context for Enterprise AI, Reinforcing Position as the Essential Platform for AI Ecosystem20.10.2026 15:00:00 EEST | Press release
ARIS, the pioneer in business process management whose powerful Enterprise Model has been the foundation for enterprise operations for more than three decades, today launched Process Context for Enterprise AI – to become the critical base layer for the agentic ecosystem, giving agents and applications the business understanding they need to deliver measurable new value. While Process Context is becoming critical for successfully deploying and scaling enterprise AI, it demands far more than simply connecting AI agents to business data. It requires a comprehensive foundation that captures the relationships between processes, people, systems, risks and controls. Built on a comprehensive Digital Twin of the Organization that connects how work is designed with the execution data that sits around it, ARIS provides this critical layer of Process Context from more than 30 years of enterprise knowledge and experience, something new entrants to the space are struggling to replicate. The importan
Hologic and Inpeco Announce Co-Marketing Partnership to Advance Molecular Laboratory Automation20.10.2026 15:00:00 EEST | Press release
Hologic, Inc., a global leader in women’s health and diagnostics, and Inpeco S.A., the global leader in Total Laboratory Automation, today announced they have signed a co-marketing partnership for Inpeco’s automation solution FlexLab™ X and Hologic’s Panther® System in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261020837126/en/ Hologic and Inpeco S.A. announce a co-marketing partnership for Inpeco's automation solution FlexLab™ X and Hologic’s Panther® System in Europe. Inpeco’s recently launched FlexLab X system enables laboratories to connect multiple Panther Systems. By combining Hologic’s fully-automated molecular diagnostics platform with FlexLab X‘s open automation capabilities, laboratories can achieve high-throughput workflows with the potential to increase sample volumes1 and enhance end-to-end sample traceability2, supporting reliable test results for optimal patient outcomes.3 The Panther System will i
Debiopharm Highlights Clinical Momentum Across DDR Portfolio at ESMO 2026, Advancing WEE1-Based Therapies in Ovarian and Uterine Cancers and Glioblastoma20.10.2026 15:00:00 EEST | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced their upcoming Phase 1/Phase 2 clinical updates at the European Society for Medical Oncology (ESMO) Congress (Madrid, Spain, 23-27 October). During the event, Debiopharm will highlight clinical updates on its pipeline targeting the DNA Damage Response (DDR), featuring single-agent data on zedoresertib (Debio 0123) as well as rational combination strategies, with both temozolomide in glioblastoma and with lunresertib (Debio2513) in solid tumors. Debiopharm’s planned activities at ESMO 2026 include: Rapid Oral Presentation (Debio 0123-GBM-105 / NCT05765812): Presenting dose escalation data evaluating zedoresertib in combination with temozolomide in patients with recurrent or progressive glioblastoma. Poster Presentation (Debio 0123-102 / NCT05109975): Presenting Phase 1 expansion data evaluating s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
